Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8762408 | 0.80 | MIF (0.52) | SIGMAR1TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2729032 | 0.80 | SLC6A2 (0.48) | SIGMAR1TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21056125 | 0.80 | SLC6A2 (0.48) | SIGMAR1TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27515553 | 0.80 | SLC6A2 (0.48) | SIGMAR1TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14391570 | 0.77 | SIGMAR1 (0.52) | SIGMAR1TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5466644 | 0.72 | TAAR1 (0.52) | SIGMAR1TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27829875 | 0.72 | SIGMAR1 (0.52) | SIGMAR1TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL888150 | 0.72 | HTR2A (0.44) | SIGMAR1TAAR1SLC6A2SLC6A4SLC6A3 | |
| Isobutylbenzene SCHEMBL5166156 | 0.71 | TAAR1 (0.50) | SIGMAR1TAAR1SLC6A2SLC6A4SLC6A3 | |
| Isobutylbenzene SCHEMBL28150610 | 0.71 | TAAR1 (0.50) | SIGMAR1TAAR1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4716223-A | LACTONIZATION | FIDIA, S.P.A. (IT) | 1987-12-29 | — | — | US | claimed |
| EP-0072722-B1 | A METHOD FOR PREPARING GANGLIOSIDE DERIVATIVES AND USE THEREOF IN PHARMACEUTICAL COMPOSITIONS | FIDIA S.p.A. (IT) | 1986-06-04 | — | — | EP | claimed |
| US-4593091-A | Ion exchanging; forming lactonic bond | FIDIA, S.P.A. (IT) | 1986-06-03 | — | — | US | claimed |
| EP-0072722-A2 | A method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions | FIDIA S.p.A. (IT) | 1983-02-23 | — | — | EP | claimed |
| EP-0072286-A1 | Organic amide compounds derived from nitrogenous lipids | FIDIA S.p.A. (IT) | 1983-02-16 | — | — | EP | claimed |
| US-7947309-B2 | Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants | FIDIA FARMACEUTICI S.P.A (IT) | 2011-05-24 | — | — | US | disclosed |
| US-20100080823-A1 | Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2010-04-01 | — | — | US | disclosed |
| US-20050226937-A1 | Use of hyaluronic acid polymers for mucosal delivery of vaccine and adjuvants | CHIRON CORPORATION (US) | 2005-10-13 | — | — | US | disclosed |
| EP-1082135-B1 | USE OF HYALURONIC ACID POLYMERS FOR MUCOSAL DELIVERY OF VACCINE ANTIGENS AND ADJUVANTS | CHIRON CORP (US) | 2004-12-22 | — | — | EP | disclosed |
| US-6824793-B1 | BIOADHESIVE PROPERTIES OF THE HYALURONIC ACID POLYMERS DECREASE THE RATE OF MUCOCILIARY CLEARANCE FROM THE NASAL CAVITY AND THUS ALLOW A LONGER CONTACT TIME BETWEEN THE ANTIGEN AND THE ABSORBING MEMBRANE | CHIRON CORPORATION | 2004-11-30 | — | — | US | disclosed |
| US-6407072-B1 | PROTEIN KINASE C INHIBITOR | FIDIA S.P.A. (IT) | 2002-06-18 | — | — | US | disclosed |
| EP-0410883-B1 | Di-lysogangliosides derivatives | FIDIA SPA (IT) | 1999-03-31 | — | — | EP | disclosed |
| US-4713374-A | Ganglioside derivatives | FIDIA, S.P.A. (IT) | 1987-12-15 | — | — | US | disclosed |
| US-4639437-A | NERVOUS SYSTEM DISORDERS | FIDIA, S.P.A. (IT) | 1987-01-27 | — | — | US | disclosed |
| EP-0072722-B1 | A METHOD FOR PREPARING GANGLIOSIDE DERIVATIVES AND USE THEREOF IN PHARMACEUTICAL COMPOSITIONS | FIDIA S.p.A. (IT) | 1986-06-04 | — | — | EP | disclosed |
| US-4593091-A | Ion exchanging; forming lactonic bond | FIDIA, S.P.A. (IT) | 1986-06-03 | — | — | US | disclosed |
| EP-0167449-A2 | New ganglioside derivatives | FIDIA S.p.A. (IT) | 1986-01-08 | — | — | EP | disclosed |
| EP-0145209-A2 | A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor | FIDIA S.p.A. (IT) | 1985-06-19 | — | — | EP | disclosed |
| EP-0072722-A2 | A method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions | FIDIA S.p.A. (IT) | 1983-02-23 | — | — | EP | disclosed |
| EP-0072286-A1 | Organic amide compounds derived from nitrogenous lipids | FIDIA S.p.A. (IT) | 1983-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080823-A1 | Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants | MUC1, CD44, ST3GAL3 | SIGMAR1 4135/4885TAAR1 3879/4885SLC6A2 4017/4885 |
| US-20050226937-A1 | Use of hyaluronic acid polymers for mucosal delivery of vaccine and adjuvants | MUC1, CD44, ST3GAL3 | SIGMAR1 4074/4885TAAR1 3864/4885SLC6A2 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.